Compare BNKK & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNKK | SCYX |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.9M | 29.8M |
| IPO Year | 2020 | 2014 |
| Metric | BNKK | SCYX |
|---|---|---|
| Price | $3.90 | $0.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 4.0M | 534.5K |
| Earning Date | 03-27-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,293,124.00 | ★ $2,932,000.00 |
| Revenue This Year | N/A | $170.77 |
| Revenue Next Year | N/A | $286.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 251.44 | N/A |
| 52 Week Low | $2.33 | $0.57 |
| 52 Week High | $46.90 | $1.31 |
| Indicator | BNKK | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 50.31 | 62.99 |
| Support Level | $3.45 | $0.69 |
| Resistance Level | $4.14 | $0.78 |
| Average True Range (ATR) | 0.67 | 0.07 |
| MACD | -0.15 | 0.00 |
| Stochastic Oscillator | 8.33 | 68.24 |
Bonk Inc is a publicly traded company focused on building a digital asset treasury centered around the BONK ecosystem on the Solana blockchain. It generates revenue through a recurring interest in the memecoin launchpad letsBONK.fun and actively manages its treasury of BONK tokens.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.